Role of immunosuppressive therapy and predictors of therapeutic effectiveness and renal outcome in IgA nephropathy with proteinuria

Archives of Medical Science

Volumn 11, Issue 2, 2015, Pages 332-339

  Ruan, Yiping ^a,b   Chen, Wenfang ^a   Li, Zhibin ^a   Tang, Xueqing ^a,b   Li, Jianbo ^a,b   Yu, Xueqing ^a,b   Yang, Qiongqiong ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

IgA nephropathy; Outcome; Predictor; Proteinuria; Therapy

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLATE MOFETIL; SERUM ALBUMIN; STEROID; TRIACYLGLYCEROL;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; COMMON COLD; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; STEROID THERAPY; SURVIVAL RATE; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

EID: 84928394351     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.50965     Document Type: Article

References (26)

1. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005; 16: 2088-97.
2. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 2004; 66: 920-3.
3. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36: 227-37.
4. Lee SM, Rao VM, Franklin WA, et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol 1982; 13: 314-22.
5. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29: 829-42.
6. Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-45.
7. Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-56.
8. Yamamoto R, Imai E. A novel classification for IgA nephropathy. Kidney Int 2009; 76: 477-80.
9. Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol 2011; 22: 1785-94.
10. Ostalska-Nowicka D, Malinska A, Silska M, Perek B, Zachwieja J, Nowicki M. Mycophenolate mofetil (MMF) treatment efficacy in children with primary and secondary glomerulonephritis. Arch Med Sci 2011; 7: 1042-8.
11. Zeng CH, Le W, Ni Z, et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients. Am J Kidney Dis 2012; 60: 812-20.
12. Shi SF, Wang SX, Jiang L, et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol 2011; 6: 2175-84.
13. Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C. The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol 2011; 6: 2384-8.
14. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2937-44.
15. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 2012; 81: 833-43.
16. Coppo R, Feehally J, Glassock RJ. IgA nephropathy at two score and one. Kidney Int 2010; 77: 181-6.
17. Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2009; 53: 26-32.
18. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24: 3694-701.
19. Kim TY, Kim SB, Park SK. The efficacy of steroid pulse therapy in patients with IgA nephropathy. Clin Nephrol 2012; 78: 100-5.
20. Lv J, Xu D, Perkovic V, et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 2012; 23: 1108-16.
21. Zhou YH, Tang LG, Guo SL, et al. Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis. PLoS One 2011; 6: e18788.
22. Pozzi C, Andrulli S, Del VL, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-63.
23. Herzenberg AM, Fogo AB, Reich HN, et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int 2011; 80: 310-7.
24. Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H. Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol 2011; 6: 2806-13.
25. Yau T, Korbet SM, Schwartz MM, Cimbaluk DJ. The Oxford classification of IgA nephropathy: a retrospective analysis. Am J Nephrol 2011; 34: 435-44.
26. Kang SH, Choi SR, Park HS, et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant 2012; 27: 252-8.